On Wednesday, Following U.S. Stocks were among the “Top Gainers”: Globalstar, (NYSEMKT:GSAT), Salix Pharmaceuticals, (NASDAQ:SLXP), On Deck Capital, (NYSE:ONDK), Mylan N.V., (NASDAQ:MYL)

Globalstar, (NYSEMKT:GSAT), with shares inclined 7.14%, closed at $3.15.

Salix Pharmaceuticals, (NASDAQ:SLXP), with shares jumped 6.95%, settled at $168.61.

On Deck Capital, (NYSE:ONDK), with shares climbed 6.75%, and closed at $18.50.

Mylan N.V., (NASDAQ:MYL), surged 6.68%, and closed at $59, hitting new 52-week high of $59.92.

Latest NEWS regarding these Stocks are depicted underneath:

Globalstar Inc. (NYSEMKT:GSAT)

Formerly on March 2, Globalstar Inc. (GSAT), declared its financial and operating results for the fourth quarter and year ended December 31, 2014.

FOURTH QUARTER FINANCIAL REVIEW:

Proceed for the fourth quarter of 2014 was $22.1 million contrast to $21.0 million for the fourth quarter of 2013, an raise of 5%, which was driven by raises in both service proceed and subscriber equipment proceed.

Service proceed was $17.2 million for the fourth quarter of 2014 contrast to $16.8 million for the fourth quarter of 2013. The primary driver of this raise was growth in SPOT service proceed, which raised 7%. The growth in SPOT service proceed was due to an 8% raise in subscribers from December 31, 2013 to December 31, 2014. The raise in the SPOT subscriber base was driven predominantly by the market introduction of the SPOT Trace product in late 2013. Net quarterly subscriber additions raised 40% from about 13,600 to about 19,000. Fourth quarter 2014 service proceed growth also reflected both Duplex and Simplex proceed growth, which raised 2% and 14%, respectively, due primarily to raises in subscribers. The raises in Duplex, SPOT and Simplex service proceed were offset partially by a decrease in other service proceed. Driving the majority of the decrease in other service proceed for the fourth quarter of 2014 as contrast to 2013 was a decrease in third-party proceed of $0.2 million, in addition to a non-cash, out of period adjustment to proceed related to an international partner of $0.4 million.

Subscriber equipment sales proceed was $4.9 million in the fourth quarter of 2014, an raise of 17% from the fourth quarter of 2013. Simplex equipment sales proceed, which was the largest contributor of the total raise, grew 48% due to higher priced units being sold in the fourth quarter of 2014 as contrast to the same period in 2013. Also contributing to the total raise in equipment sales proceed was a 9% raise in SPOT equipment sales proceed.

Net revenue was $92.0 million for the fourth quarter of 2014 as contrast to a net loss of $234.8 million for the fourth quarter of 2013. This fluctuation results primarily from the influence of non-cash gains in the fourth quarter of 2014 due to a decrease in the value of the Corporation’s derivative liabilities. This decrease in value was driven primarily by the decrease in the Corporation’s stock price during the fourth quarter of 2014. Conversely, the influence of non-cash losses during the fourth quarter of 2013 was due to an raise in the value of the Corporation’s net derivative liabilities during the fourth quarter of 2013, which was driven primarily by the raise in the Corporation’s stock price during the fourth quarter of 2013. The fourth quarter of 2014 was also favorably influenced by lower interest expense of $9.4 million as contrast to $28.0 million in the 2013 quarter driven primarily by conversions of our 5% Notes during 2013 that did not recur in 2014. Depreciation expense declined 19% to $19.8 million in the fourth quarter of 2014 as contrast to $24.5 million in the 2013 quarter due to the depreciable lives of certain first-generation assets coming to an end in 2014.

Offsetting these reductions in expenses was an $8.6 million raise in the reduction of carrying value of inventory from $5.8 million recorded during the fourth quarter of 2013 to $14.4 million during the fourth quarter of 2014. The inventory impairment charge recorded during the fourth quarter of 2014 related primarily to a reduction in the carrying value of Duplex phones, antennas, ancillary parts and car kit bases.

Adjusted EBITDA for the three-month periods ended December 31, 2014 and 2013 was $3.8 million and $3.9 million, respectively. This decrease in Adjusted EBITDA was due to a $1.5 million raise in proceed offset by a $1.6 million raise in expenses (both not including EBITDA adjustments). The raise in expenses in the fourth quarter of 2014 was driven primarily by the higher cost of subscriber equipment sales, which grew in line with equipment proceed. Additionally, a rebate program introduced during 2014 influenced proceed generated from Duplex equipment sales and raised subscriber attainment costs.

Globalstar provides mobile satellite voice and data services. Globalstar offers these services to commercial customers and recreational consumers in more than 120 countries around the world. The Corporation’s products comprise mobile and fixed satellite telephones, simplex and duplex satellite data modems, flexible airtime service packages and the SPOT family of mobile satellite consumer products counting the SPOT Satellite GPS Messenger.

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP)

Valeant Pharmaceuticals International, Inc. (VRX) (VRX) issued the below statement in response to Endo International PLC’s (ENDP) unsolicited offer to attain Salix Pharmaceuticals Ltd. (SLXP).

“We are firmly committed to our all-cash agreed transaction, which delivers immediate and certain value to Salix shareholders. The tender offer is planned to expire at the end of the day on March 31, 2015, and Valeant anticipates to be in the position to close the transaction on April 1, 2015.”

On February 22, 2015 Valeant and Salix declared a definitive contract under which Valeant will attain all of the outstanding ordinary stock of Salix for $158 per share in cash. The transaction is subject to customary closing conditions and regulatory approval.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) is a multinational specialty pharmaceutical corporation that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics.

Salix Pharmaceuticals, Ltd. attains, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States.

On Deck Capital, Inc. (NYSE:ONDK)

Empire State Realty Trust, Inc. (ESRT) declared that On Deck Capital, Inc. (ONDK), expanded its headquarters space at 1400 Broadway by about 79,000 square feet.

The corporation will grow within the property from about 38,000 square feet to a total occupancy of about 117,000 square feet.

OnDeck is a leading platform for small business loans. The corporation uses proprietary lending technology and analytics to aggregate and analyze thousands of data points to assess the creditworthiness of small businesses. Since 2007, OnDeck has deployed more than $2 billion in capital and has served tens of thousands of small businesses across more than 700 different industries in all 50 U.S. states, and also makes small business loans in Canada.

Paul Ippolito of Newmark Grubb Knight Frank represented OnDeck in the lease negotiations. Landlord representation was offered by Keith A. Cody of ESRT, together with Scott Klau, Erik Harris and Neil Rubin of Newmark Grubb Knight Frank.

Empire State Realty Trust, Inc. (ESRT), a leading real estate investment trust (REIT), owns, manages, operates, attains and repositions office and retail properties in Manhattan and the greater New York metropolitan area, counting the Empire State Building, the world’s most famous office building. Headquartered in New York, New York, the Corporation’s office and retail portfolio covers 10.0 million rentable square feet, as of December 31 2014, compriseing of 9.3 million rentable square feet in 14 office properties, counting nine in Manhattan, three in Fairfield County, Connecticut and two in Westchester County, New York; and about 728,000 rentable square feet in the retail portfolio.

On Deck Capital, Inc. provides financing products to small businesses in the United States. It offers fixed term loans and revolving line of credit. The corporation processes and services its loans through its online platform.

Mylan N.V. (NASDAQ:MYL)

Mylan N.V. (MYL), and Mylan Inc. declared the U.S. launch of Buprenorphine Hydrochloride Sublingual Tablets, 2 mg and 8 mg, which is the generic version of Reckitt Benckiser’s Subutex® Sublingual Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of opioid dependence and is preferred for induction.

Buprenorphine Hydrochloride Sublingual Tablets, 2mg and 8mg had U.S. sales of about $107.8 million for the 12 months ending December 31, 2014, according to IMS Health.

Presently, Mylan has 281 ANDAs pending FDA approval representing $104.6 billion in annual brand sales, according to IMS Health. Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $27.3 billion in annual brand sales, for the 12 months ending June 30, 2014, according to IMS Health.

Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.